World Games

Sportradar Reports First Quarter 2024 Financial and Operating Results

Retrieved on: 
onsdag, maj 15, 2024
Partnership, Share repurchase, ATP, Total revenue, Tennis, Customer, World Games, Esports, Sport, Growth, NBA, Form 6-K, CBA, Annual report, UTR, Odds, Adjustment, Webcast, Computer vision

ST. GALLEN, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • Sportradar made Fast Company’s 2024 list of Most Innovative Companies in sports for the Company’s leading Computer Vision technology and Enhanced Table Tennis solution.
  • Total Revenue for the current quarter was €265.9 million, up 28% year-over-year driven by growth across the portfolio, in particular Betting Technology & Solutions.
  • As a percentage of total company revenues, Betting Technology & Solutions represented 82% of total company revenue in the current quarter as compared to 78% in the prior year quarter.
  • Sportradar will host a conference call to discuss the first quarter 2024 results today, May 15, 2024, at 8:30 a.m. Eastern Time.

Global Carbon Nanomaterials Markets Report 2024-2033: Demand, Production Capacities, Pricing, Main Producers, and Applications - ResearchAndMarkets.com

Retrieved on: 
måndag, maj 13, 2024
Chemicals, Plastics, Natural Resources, Manufacturing, Mining, Minerals, Carbon, Polymer, Fullerene, Membrane, Nanostructure, Market, Diamond, Graphite, World Games, Nanodiamond, Electronics, MXenes, Carbon fibers

The "The Global Market for Carbon Nanomaterials 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Market for Carbon Nanomaterials 2024-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Global Market for Carbon Nanomaterials 2024-2033 provides a comprehensive analysis of advanced carbon nanomaterials including graphene, carbon nanotubes, carbon nanofibers, fullerenes, nanodiamonds, graphene quantum dots, and nanomaterials from carbon capture and utilization.
  • The report examines global demand, production capacities, pricing, main producers, and applications across major end-user markets such as electronics, energy storage, membranes, coatings, polymers, biomedical devices, and sensors.
  • Regional demand forecasts across North America, Europe, Asia Pacific, Rest of World
    Impact of graphene and nanomaterials on batteries, electronics, membranes, coatings
    Profiles of 590+ leading producers/suppliers of carbon nanomaterials.

EQS-News: ElringKlinger enjoys solid start to 2024 financial year

Retrieved on: 
fredag, maj 10, 2024
Depreciation, World Games, Environment, Tax, ElringKlinger, Growth, Film industry

The Group generated revenue of EUR 465.3 million in the period just ended (Q1 2023: EUR 487.7 million).

Key Points: 
  • The Group generated revenue of EUR 465.3 million in the period just ended (Q1 2023: EUR 487.7 million).
  • Asked to comment on the quarterly results, Thomas Jessulat, CEO of ElringKlinger, said "Overall, we succeeded in further reinforcing our financial base in the quarter under review.
  • The ElringKlinger Group’s financial position and cash flows remained very solid in the first quarter of 2024, with an equity ratio of 44.5% (Q1 2023: 44.4%) and a net debt-to-EBITDA ratio of 1.7 (Q1 2023: 2.0).
  • Although the economic environment remains challenging, ElringKlinger anticipates slight organic growth in revenue and, as regards earnings performance, an adjusted EBIT margin of around 5% for the 2024 financial year.

Pharming Group reports first quarter 2024 financial results and provides business update

Retrieved on: 
onsdag, maj 8, 2024
VWAP, VUS, FDA, Phase, Haploinsufficiency, IRP, Iberian languages, Laboratory, Safety, Euronext Amsterdam, Pharmacokinetics, PTEN, Epidemiology, CTLA4, Marketing, World Games, APDS, Health care, MAA, CHMP, Trial of the century, Genetic testing, Disease, Patient, Physician, EMA, Primary immunodeficiency, Ministry, Variant, Committee, MHRA, Diagnosis, Pids, PID, Lymphocyte, Clinical trial, Government, Microsoft Access, Prevalence, Ageing, Pharmaceutical industry

“Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.

Key Points: 
  • “Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.
  • Pharming made continued progress in the first quarter of 2024 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.
  • Pharming announced completion of enrollment in the clinical trial for children ages 4 to 11 years old on April 8, 2024.

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
tisdag, maj 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
torsdag, mars 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies

Retrieved on: 
onsdag, mars 13, 2024
Diagnosis, Checkmate, Prevalence, Patient, World Games, SWOT, Biomarker, Research, NCCN, Cancer, EMA, Contract research organization, National Comprehensive Cancer Network, Protein, Medicine, Clinical trial, Drug development, Therapy, Precision, FDA, Pharmaceutical industry

Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.

Key Points: 
  • Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.
  • The Precision Oncology - Global Clinical Trial Landscape whitepaper is designed for researchers, clinicians, pharmaceutical, biopharma and biotech firms.
  • It presents a thorough analysis of healthcare, technology, macroeconomic, regulatory trends, SWOT analysis, funding, and innovative research developments in precision oncology.
  • The report provides a detailed review of the current precision oncology landscape including standout trials, important trends around FDA approvals, funding initiatives, and ongoing insights impacting research and development.

Impact Podcast with John Shegerian to Present Special Three-Part Series Featuring In-Depth Interview with Jeanette Lee

Retrieved on: 
torsdag, april 4, 2024
Women, Sports, Publishing, Entertainment, Communications, Books, Lifestyle, Consumer, Billiards, Podcast, ESPN, Entrepreneurship, Doc, Black widow, Amazon Music, Gold, Doc NYC, Female, Black, Google Podcasts, WPBA Tour, Memoir, Nature, Life, ERI, Amazon (company), World Games

Champion professional pool player Jeanette Lee , is the subject of a special three-part, in-depth conversation this weekend on the Impact Podcast with John Shegerian .

Key Points: 
  • Champion professional pool player Jeanette Lee , is the subject of a special three-part, in-depth conversation this weekend on the Impact Podcast with John Shegerian .
  • An icon of her sport, Lee was born to Korean-immigrant parents in Brooklyn in 1971.
  • A documentary about her life, Jeanette Lee Vs., premiered at the Doc NYC film festival and is part of the ESPN series 30 for 30.
  • In the Impact Podcast interview, Lee shares details of her rise to fame and how she conquered a unique combination of challenges to get to where she is today.

2026 Special Olympics USA Games Calls New Champions to its Board of Directors

Retrieved on: 
torsdag, mars 21, 2024
People with Disabilities, Olympics, Sports, Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Fund Raising, Consumer, Foundation, Other Philanthropy, Well, Baseball, Second Continental Congress, Congress, Sport, University of Minnesota, First lady, Special Olympics USA, Special Olympics World Games, Prison, Chairperson, Special, Strategic planning, CBO, University, Sunshine Studios, Meka, Chicago Bears, Life, Athlete, Minnesota Twins, Special Olympics, New York Yankees, Olympic Games, LGBTQ, Love, Disability, Movement, Chicago White Sox, World Games, Major League Baseball, Teaching, Management

Special Olympics today appointed seven new leaders to the organization's 2026 Special Olympics USA Games Board of Directors to help oversee the national celebration of inclusivity that will bring together thousands from all 50 states to Minnesota.

Key Points: 
  • Special Olympics today appointed seven new leaders to the organization's 2026 Special Olympics USA Games Board of Directors to help oversee the national celebration of inclusivity that will bring together thousands from all 50 states to Minnesota.
  • “We are thrilled to add seven new members to our existing board of directors who are dedicated to leading the 2026 USA Games with the same joy, excitement and inclusivity our athletes demonstrate each time they compete,” said Adam Hjerpe, Board Chair, 2026 Special Olympics USA Games.
  • I look forward to helping the 2026 Special Olympics USA Games Board of Directors ensure the 2026 USA Games leaves a lasting and memorable legacy within our community and beyond.”
    The seven new members appointed to the 2026 Special Olympics USA Games Board of Directors are:
    Gwen Walz: Gwen is the First Lady of Minnesota, a former English teacher and lifelong Minnesotan.
  • These leaders join the existing board members of the 2026 Special Olympics USA Games, including Adam Hjerpe, board chair; Christy Sovereign, CEO, 2026 Special Olympics USA Games; Terry Clark, co-presenting partner, United Healthcare; Caroline Jones, co-presenting partner, Jersey Mike’s Subs; Dave Dorn, president, Special Olympics Minnesota; Wendy Blackshaw, CEO, Minnesota Sports and Events; Jon Steadland, chief of staff, office of the president, University of Minnesota; David Booth, athlete representative, Special Olympics Minnesota; and Will Smith, athlete representative, Special Olympics of New York.

Global Classic Car Insurance Market Report 2024 with Analyst Recommendations: Focus on Streamlining the Operations and Enhance Customer Experience through Online Platforms - ResearchAndMarkets.com

Retrieved on: 
tisdag, mars 12, 2024
Professional Services, Insurance, Performance & Special Interest, Automotive, Online, Theft, Channel, Growth, Porter's five forces analysis, Risk, World Games, SWOT, Investment, USD

The Global Classic Car Insurance market showcased growth at a CAGR of 7.11% during 2019-2022.

Key Points: 
  • The Global Classic Car Insurance market showcased growth at a CAGR of 7.11% during 2019-2022.
  • The report analyses the Classic Car Insurance Market by Region (North America, Europe, and Rest of World) and 6 Countries (United States, Canada, Germany, United Kingdom, France, and Italy).
  • The report analyses the Classic Car Insurance Market By Vehicle Type (Vintage, and Classic).
  • The report analyses the Classic Car Insurance Market By Channel (Direct Sales, Agents/Brokers, and Online Platforms).